Adagene completes enrollment in phase 2 trial of muzastotug
Adagene Inc. (ADAG) completed enrollment in a Phase 2 trial of muzastotug, an anti-CTLA-4 antibody therapy, combined with Merck’s KEYTRUDA for late-line colorectal cancer. The trial enrolled 60 patients, with results expected in early 2027. The FDA confirmed Phase 3 trial design elements, and Sanofi invested in the trial. Muzastotug has FDA Fast Track designation.
How this was made
The 30-second read
Why it matters
The enrollment milestone validates trial design and may attract further capital or partnership interest, but the stock remains speculative until efficacy data are released.
Market read
First‑report of a Phase 2 enrollment completion for a biotech candidate; likely short‑term price movement and longer‑term valuation impact.
What to watch
Sanofi's equity investment could signal strategic partnership benefits, but also potential dilution concerns.
Background
Adagene is developing muzastotug, a precision‑masked anti‑CTLA‑4 antibody, with Fast Track designation and a planned Phase 3 trial.
Ticker impact
Adagene announced completion of enrollment in its Phase 2 dose‑optimization trial of muzastotug, a new anti‑CTLA‑4 antibody, with results expected in early 2027.
potential upside as investors price in the upcoming Phase 2 read‑out and future Phase 3 trial prospects.
First‑report of a pivotal trial step for a biotech; such news historically drives short‑term buying pressure despite long‑term uncertainty.
Market effects
May boost sentiment for the broader oncology‑biotech sector as a new anti‑CTLA‑4 candidate advances.
Limited to U.S. biotech investors; no immediate regional effect.
Modest global relevance, primarily affecting biotech and specialty pharma investors.
Counterpoint
If Phase 2 data disappoint, the stock could face sharp downside; investors should weigh execution risk.
Key entities
- companyAdagene Inc.
Biotech firm developing muzastotug.
- companyMerck
Partner providing KEYTRUDA (pembrolizumab) in the trial.
- companySanofi
Equity investor supporting the trial.

